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Purpose: We evaluated the impact of renal tumor size on the oncologic and surgical effi-
cacy of laparoscopic renal cryosurgery (LRC) according to our intermediate-term expe-
rience in Korea.
Materials and Methods: From June 2005 to October 2008, we enrolled 37 patients who 
underwent LRC for 40 renal tumors. Patients were stratified into four groups according 
to renal tumor size. Patients who presented with a maximum tumor diameter (MTD) 
of at least 1 cm but less than 2 cm were assigned to Group 1, those with an MTD equal 
to or greater than 2 but less than 3 cm were assigned to Group 2, those with an MTD 
equal to or greater than 3 but less than 4 cm were assigned to Group 3, and those with 
an MTD equal to or greater than 4 cm were assigned to Group 4. Oncologic and clinical 
outcomes in each group were compared.
Results: The four groups showed no statistically significant differences in preoperative 
variables, including age, sex, body mass index, American Society of Anesthesiologists 
scores, baseline renal function and hemoglobin, and length of hospital stay. Regarding 
surgical aspects, however, operation time, estimated blood loss, and postoperative com-
plications were significantly increased in patients with larger tumors. Three patients 
in Group 3 required postoperative transfusions, and 1 patient in Group 4 required con-
version to open renal cryosurgery. During the mean follow-up period of 31.6 months, 
radiologic evidence of tumor recurrence was found in only 2 patients in Group 4.
Conclusions: In this series, LRC for renal tumors smaller than 3 cm was conducted safe-
ly without radiologic evidence of tumor recurrence during intermediate-term follow-up. 
For tumors larger than 3 cm, however, the transfusion rate increased, and for renal 
tumors larger than 4 cm, the tumor recurrence rate increased significantly.
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INTRODUCTION
The increased use of cross-sectional images has led to renal 
tumor “stage migration,” with the diagnosis of most masses 
occurring at an early stage [1]. Consequently, the size of 
newly diagnosed renal tumors has decreased, and the in-
cidence of small renal tumors (less than 4 cm) has increased 
[2]. Surgical resection, predominantly by nephron-sparing 
surgery, is considered the standard of care for clinically lo-
calized renal cell carcinoma (RCC) because of the favorable 
prognosis associated with surgery and the relative in-
effectiveness of systemic therapy. The advantages of this 
approach include the preservation of renal function and on-
cologic efficacy in terms of tumor recurrence and the 
long-term survival rate comparable to that of radical neph-
rectomy, which is the traditional treatment modality for re-
nal tumors [3-5]. Along with advancements in minimally 
invasive approaches, laparoscopic partial nephrectomy 
(LPN) has been reported to have oncological efficacy com-
parable to that of open partial nephrectomy. LPN requires 
high laparoscopic dexterity, however, and, even for experi-
enced hands, still requires a longer warm ischemic time 
and is associated with more complications than is open par-
tial nephrectomy [6,7].
　With the increasing application of minimally invasive 
surgery, several energy-based tissue-ablation technolo-
gies, including cryoablation and radiofrequency ablation, 
are being investigated. With these techniques, tissue is de-Korean J Urol 2010;51:171-177
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stroyed by in situ ablation instead of extirpation; thus, com-
plications induced by renal ischemia and surgical excision 
can be avoided. The data suggest that of the alternative 
ablation modalities, cryoablation may result in signi-
ficantly lower rates of local tumor progression compared 
with radiofrequency ablation techniques [8]. In particular, 
compared with a percutaneous approach, laparoscopic re-
nal cryoablation (LRC) allows the surgeon to position the 
cryoprobe with greater precision by using intraoperative 
ultrasonography and to move adjacent organs away from 
the ablation site; also, bleeding can be monitored and con-
trolled during the procedure [9].
　However, for large renal tumors, an increased tumor re-
currence rate and complications after LRC have recently 
been reported [10]. To validate the impact of renal tumor 
size on oncologic and surgical efficacy, we retrospectively 
evaluated the oncologic and surgical effects of LRC accord-
ing to renal tumor size from our intermediate-term experi-
ence in Korea.
PATIENTS AND METHODS
From June 2005 to October 2008, 37 patients in our in-
stitution underwent LRC for 40 renal tumors; the tumors 
were solid and were observed in radiologic findings, includ-
ing computed tomography (CT) and magnetic resonance 
imaging (MRI). Indications for LRC included a high risk for 
partial nephrectomy or patient age greater than 70 years. 
High operative risk in our institution was defined as an 
American Society of Anesthesiologists (ASA) score of 3 or 
more. Among these inclusion criteria for LRC, absolute in-
dications included bilateral tumors and patients with a 
solitary kidney or renal insufficiency. A patient with nor-
mal contralateral renal function but poor operability was 
defined as having an elective indication. Detailed in-
formation on all treatment methods, including radical 
nephrectomy, partial nephrectomy, and laparoscopic renal 
cryosurgery was given to all patients before surgery.
　Patients were stratified into four groups according to re-
nal tumor size as follows: Group 1 included patients pre-
senting with tumors with a maximum tumor diameter 
(MTD) of at least 1 but less than 2 cm, Group 2 included 
those with tumors of at least 2 but less than 3 cm, Group 
3 included tumors that were at least 3 but less than 4 cm, 
and Group 4 included tumors that were 4 cm or larger.
　For those groups, perioperative variables, including 
ASA score, comorbidity, body mass index (BMI), baseline 
renal function, hemoglobin, tumor location and size, oper-
ative time, estimated blood loss, transfusion rate, duration 
of hospitalization, postoperative complications, post-
operative renal function, and hemoglobin levels were eval-
uated retrospectively. Also, the results of the pathologic ex-
amination, which was conducted at the time of cryoa-
blation and radiologic follow-up for recurrence and meta-
stasis, were evaluated. Patients were initially evaluated at 
1 and 3 months and then every 3 months during the first 
year. They were evaluated every 6 months during the sec-
ond year, and then annually. Follow-up evaluations in-
volved a medical history update, physical examination, 
blood pressure check, contrast-enhanced CT or MRI, chest 
radiography, measurement of serum electrolytes, and re-
nal function tests. Lack of enhancement on CT or MRI along 
with stable or decreased tumor size was considered a sign 
of successful treatment. Recurrence was defined as in-
creasing tumor size or lack of tumor shrinkage, as shown 
with image enhancement.
　Postoperative biopsies were not performed routinely in 
this series and were performed only in cases of suspicious 
tumor recurrence as determined by radiological evalua-
tion. The TNM staging system, revised by the Interna-
tional Union against Cancer (UICC, 2002), was used to de-
fine cancer stages.
　A single surgeon performed all LRC procedures. Stan-
dardized instruments with three ports were used for the 
laparoscopic procedure. Tumors anterior to a horizontal 
line within the coronal plane through the renal hilum were 
generally approached transperitoneally. Tumors posteri-
or to this line were approached retroperitoneally. Real- 
time intraoperative ultrasonography (Aloka Dynaview II, 
Americanlab, Miami, USA) was used in all cases to identify 
the lesion and to determine the position of the cryoprobe 
within the lesion. Intraoperative ultrasonography was al-
so used to identify the extension of the ice-ball during the 
freezing cycle. The kidney was mobilized and the Gerota’s 
fascia was opened to facilitate identification of the tumor. 
Fat overlying the tumor was retrieved for pathological 
examination. Depending on the tumor size before insertion 
of the cryoprobe, one or two needle biopsies were taken from 
the tumor. We used two types of cryoprobes, both with a di-
ameter of 1.47 mm. A cryoprobe (Oncura, Plymouth 
Meeting, USA) that induced a −40
oC isothermal lesion 
measuring 8 mm in diameter was used from June 2005 to 
December 2006, and the IceRod
TM (Oncura), which induced 
a −40
oC isothermal lesion measuring 14.5 mm in diameter 
and radiating from the ablation probe was used from 
January 2007 on. Before insertion into the kidney, the 
proper number and locations of the cryoprobes were care-
fully calculated on the basis of the preoperative imaging 
study and intraoperative ultrasonography. Two temper-
ature probes were then inserted into the middle and pe-
ripheral margins of the tumor to ensure that the temper-
ature within the tumor had dropped below −40
oC, which 
is normally required for effective destruction of malignant 
renal tissue. A double-freeze cycle was applied in all cases, 
with an intervening thawing process. Hemostasis was ach-
ieved by filling the probe tract with fibrin glue (Baxter, 
Deerfield, USA) and Surgicel (Johnson & Johnson, Irvine, 
USA) after the second thaw to allow for safe removal of the 
cryoprobe.
　SPSS 12.0 for Windows (SPSS Inc., Chicago, USA) was 
used for statistical analysis, and the Kruskall-Wallis and 
Pearson’s chi-square test were used for analysis of the char-
acteristics (operative time, oncological outcomes, perioper-
ative complications, etc.) of each group.Korean J Urol 2010;51:171-177
The Impact of Renal Tumor Size on the Efficacy of LRC 173
TABLE 1. Preoperative characteristics
Characteristics
Group 1 
(1.0-1.9 cm)
Group 2
(2.0-2.9 cm)
Group 3
(3.0-3.9 cm)
Group 4 
(≥4 cm)
p-value
a
No. of patients
No. of tumors
Mean age (years)
　Male
　Female
　% of male
Mean size of renal mass (cm)
Location of tumor
　Right side (52%)
　Left side (48%)
BMI (kg/m
2)
ASA score
　ASA 1
　ASA 2
　ASA 3
　ASA 4
Baseline serum creatinine (μmol/l)
Baseline hemoglobin (g/dl)
13
15
68.0 (54-75)
10
3
76%
1.5 (1.0-1.7)
9
6
23.8 (20.7-27.2)
1
5
7
0
1.37 (0.6-3.8)
14.0 (10.9-16.5)
10
10
62.42 (43-72)
6
4
  60%
2.14 (2.0-2.4)
4
6
22.6 (17.5-26.3)
0
3
6
0
1.0 (0.5-1.6)
13.27 (12-15.1)
10
11
67.36 (55-77)
5
5
  50%
3.28 (3.0-3.7)
6
5
24.4 (19.6-29.1)
1
3
6
0
1.02 (0.7-1.6)
13.84 (11.3-15.7)
4
4
59.0 (53-67)
3
1
  75%
5.07 (4-7.5)
2
2
25.5 (24.4-26.5)
0
1
3
0
0.9 (0.7-1.1)
13.27 (10.6-15.8)
0.17
0.974
0.001
0.803
b
0.44
0.855
b
0.715
0.673
MTD: maximum tumor diameter, BMI: body mass index, ASA: American Society of Anesthesiologistst, 
a: Kruskal Wallis test, 
b: Pearson’s
chi-square test
TABLE 2. Perioperative characteristics
Characteristics
Group 1 
(1.0-1.9 cm)
Group 2
(2.0-2.9 cm)
Group 3
(3.0-3.9 cm)
Group 4 
(≥4 cm)
p-value
Operation time (min)
Mean hospital stay (ml)
EBL (ml)
Pathologic results
　Renal cell carcinoma (77%)
　Angiomyolipoma (23%)
Complications
Recurrence of  tumor
Metastasis
128.3 (110-162)
3.5 (3-6)
78.3 (0-120)
13
2
0
0
0
121.4 (115-135)
4.14 (3-8)
89.6 (0-150)
6
4
0
0
0
161.9 (120-185)
4.36 (3-7)
116 (30-150)
8
3
3
0
0
205.0 (150-220)
4.25 (4-8)
123.2 (50-150)
4
1
2
0
0.045
a
0.138
a
0.018
a
0.007
b
0.003
b
MTD: maximum tumor diameter, EBL: estimated blood loss, 
a: Kruskal Wallis test, 
b: Pearson’s chi-square test
RESULTS
The preoperative characteristics of each patient group are 
summarized in Table 1. The mean follow-up period was 
31.6 (range, 18-49) months. There were 13 patients (15 tu-
mors) in Group 1, 10 patients (10 tumors) in Group 2, 10 
patients (10 tumors) in Group 3, and 4 patients (4 tumors) 
in Group 4. Mean tumor size was 1.5 cm (range, 1.0-1.7 cm) 
in Group 1, 2.14 cm (range, 2.0-2.4 cm) in Group 2, 3.28 cm 
(range, 3.0-3.7 cm) in Group 3, and 5.07 cm (range, 4-7.5 
cm) in Group 4, and the difference was significant (p= 
0.001). However, mean age, sex, BMI, ASA score, baseline 
hemoglobin, and serum creatinine showed no statistically 
significant differences (Table 1).
　Perioperative outcomes are summarized in Table 2. 
Operative time and estimated blood loss showed a sig-
nificantly different increase in each group (p=0.045, 0.018), 
with an increasing trend in patients with larger tumor size. 
Mean operative time and estimated blood loss were 128 mi-
nutes and 78 ml in Group 1, 121 minutes and 90 ml in Group 
2, 162 minutes and 116 ml in Group 3, and 205 minutes and 
123 ml in Group 4. The results for mean hospital stay were 
similar (Table 2).
　There were no postoperative complications, including 
postoperative transfusion, in Groups 1 and 2; however, 
three patients in group 3 required postoperative transfu-
sion, and one patient in group 4 required open conversion 
for control of bleeding from the cryoprobe insertion site. 
Due to her religious creed, which prohibits blood trans- 
fusion, open cryoablation with meticulous bleeding con-
trol, instead of partial nephrectomy, was conducted for this 
patient. With the exception of these cases, none of the other 
patients experienced complications.Korean J Urol 2010;51:171-177
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FIG. 1. (A) A 65-year-old female pa-
tient with a renal mass in the left 
solitary kidney that measured 7.5 cm. 
The arrow shows an ill-defined rim 
enhancement near the mass lesion at 
1 month after left laparoscopic renal 
cryoablation by abdominal MRI scan 
(T1 images). (B) A 34-year-old female 
patient with a completely endophytic 
renal mass in the left kidney that 
measured 4.0 cm. The arrow shows a 
local recurrence near the mass lesion 
at 3 months after left laparoscopic 
renal cryoablation by abdominal pel-
vic CT scan.
　During the mean follow-up period of 31.6 months, radio-
logic evidence of tumor recurrence was found in 2 cases 
(5%), both in Group 4 (Fig. 1). One patient was a 65-year-old 
female with a history of cerebral infarction. She had a left 
solitary kidney and a tumor that measured 7.5 cm. One 
month after the initial LRC, contrast enhancement was ob-
served by MRI at the surgical site (Fig. 1A). For this patient, 
open partial nephrectomy was conducted, with no findings 
of recurrence on radiological follow-ups after 9 months. 
Another patient was a 34-year-old female with a 4.0 cm en-
dophytic enhancing mass in her left kidney. Due to her reli-
gion, which prohibits blood transfusion, she chose LRC in-
stead of conventional operation. Contrast enhancement 
was still observed by CT performed 3 months after the ini-
tial LRC (Fig. 1B). We recommended another session of 
LRC, but after that the patient was lost to follow-up. All oth-
er patients, with the exception of these two, have remained 
free of recurrence or metastasis (Fig. 2).
DISCUSSION
Treatment options for small renal masses have expanded 
over the past decade. The increased use of cross-sectional 
imaging has led to “stage migration,” with the diagnosis of 
most masses occurring at an early stage. For these small 
renal masses, open partial nephrectomy has replaced radi-
cal nephrectomy as the treatment of choice. As the result 
of its minimal invasiveness and promising oncologic out-
come, LPN has gained interest; however, it is also asso-
ciated with a higher rate of complications and a longer 
learning curve than that for open partial nephrectomy [11]. 
Ablation using a cryoprobe or radiofrequency probes offers 
the advantages of being a minimally invasive surgery with 
a significantly lower rate of complications when compared 
with LPN [12]. Furthermore, many of these masses are be-
ing diagnosed in elderly patients with co-morbidities, who 
are not good candidates for partial nephrectomy or a major 
surgical procedure.
　In situ thermal destruction of renal masses through the 
creation of lethally cold temperatures offers a safer alter-
native. In addition, many early and intermediate-term re-
ports have shown promising results for LRC. The goal of 
a cryoablative procedure is to inflict lethal freezing injury 
on the tumor volume while sparing normal healthy tissues. 
Although animal studies on renal cryosurgery have been 
reported since 1974 [8], reports on clinical application for 
human renal tumors are relatively recent. After the first 
human study on percutaneous cryosurgery was reported 
by Uchida et al in 1995 [9], open and laparoscopic surgeries 
were reported by Delworth et al in 1996 and Gill et al in Korean J Urol 2010;51:171-177
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FIG. 2. (A) A 63-year-old female patient with a 3.9 cm left renal cell carcinoma (RCC). The figure shows the decreased size of the 
treated RCC in the left kidney without a definite viable portion at 3 months and 24 months after left laparoscopic renal cryoablation 
by abdominal CT scan. (B) A 55-year-old male patient with a right RCC that measured 3.1 cm. The figure shows the decreased size 
of the treated RCC in the right kidney, without a definite viable portion at 3 months and 24 months after right laparoscopic renal 
cryoablation by abdominal CT scan.
1998, respectively [11,12]. Since these promising initial re-
ports, an increasing body of literature on this new modality 
has been released. In terms of safety, low incidence rates 
of renal failure, transfusion, and urinary leakage have 
been reported from clinical and animal studies so far 
[13-15]. Renal cryosurgery has been performed via open, 
laparoscopic, and percutaneous approaches by using cry-
oprobes with diameters ranging from 1.4 mm to 5.0 mm. 
In particular, laparoscopic renal cryosurgery, which has 
been more popular than the percutaneous approach, has 
the advantage of being able to identify the exact location 
of the cryoprobes and the lesion by use of intraoperative ul-
trasonography [16]. In addition, the laparoscopic approach 
allows for displacement of adjacent organs from the cyroab-
lated site, thus decreasing the possibility of iatrogenic 
injuries.
　Although no long-term follow-up data are currently 
available, most studies on this issue have reported promis-
ing oncologic control in early to intermediate-term fol-
low-ups. Two published LRC series with a minimum fol-
low-up period of 3 years demonstrated radiographically 
documented success rates of 97% and 96%, respectively 
[14]. Moinzadeh et al reported tumor recurrences in 3 of 56 
tumors (5.4%) after LRC with a mean follow-up period of 
36 months [17]. Schwartz et al reported recurrences in 2 
patients among 50 tumors (4%) after LRC with a mean fol-
low-up period of 10 months [18]. In this series with a mean 
follow-up period of 31.6 months, oncologic efficacy (radio-
logic recurrence of 5%) was comparable with that of pre-
vious studies. The rates of recurrence after LRC were also 
similar to those after LPN. Desai et al compared the out-
come of 89 LRC procedures with those in 153 patients who 
underwent LPN [19]. The recurrence rate after LPN was 
0.6% for an average follow-up period of 5.8 months and that 
after LRC was 3.0% for an average follow-up period of 24.6 
months. Interestingly, estimated blood loss and the rate of 
postoperative complications were higher for LPN than for 
LRC (211 ml vs. 110 ml and 11.1% vs. 3.3%, respectively). 
Weight et al evaluated the efficacy of LRC in 109 tumors 
compared with 192 renal tumors treated by percutaneous 
radiofrequency ablation (RFA) [20]. The rate of radio-
logical success, which was defined as no contrast enhance-Korean J Urol 2010;51:171-177
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ment on follow-up images for 6 months, was 85% after RFA 
and 90% after LRC. Pathological success rates, which were 
assessed 6 months after the initial ablation, were 64.8% for 
RFA and 93.8% for LRC.
　Radiographic follow-up after cryoablation is the primary 
means of assessing the effect of treatment [21], and en-
hancement on post-contrast imaging is considered evi-
dence of incomplete treatment of disease. Groups at some 
centers have performed biopsy after ablation for assess-
ment of disease viability, whereas others have relied only 
on radiographic evaluation. Wright et al demonstrated ex-
cellent correlation between post-cryoradiographic find-
ings and subsequent percutaneous biopsy of treated le-
sions, reporting that no lesion that failed to show enhance-
ment on post-treatment imaging revealed evidence of a via-
ble tumor [22]. In addition, biopsy can lead to false-neg-
ative results. On the basis of these findings, we did not use 
the staged postoperative histology for radiologically re-
sponding cases initially described by Desai and colleagues 
[19].
　Although minor complications including transfusion oc-
curred, major complications including urinary leakage, 
which is the most serious complication reported after renal 
cryosurgery, did not occur during our series. The low in-
cidence of complications when performing LRC might be 
associated with the small diameter of the cryoprobe. 
Compared with larger-sized cryoprobes, the ultrathin 1.47 
mm cryoprobes that were used in our series are associated 
with a relatively low risk of complications from bleeding or 
disastrous renal fracture [23]. Surgery-related problems, 
such as urine leakage, nephrectomy for bleeding, and ad-
jacent organ damage have occurred in studies that used 
cryoprobes with a relatively large diameter. In contrast, no 
major complications were reported in three previous stud-
ies, including our own, that used ultrathin cryoprobes of 
1.47 mm.
　Another advantage of using ultrathin 1.47 mm cryop-
robes is that multiple cryoprobes can be used for small le-
sions [24]. For reliable tumor destruction and for obtaining 
an adequate margin for the ice-ball, exact positioning of the 
cryoprobe in the center and peripheral margin of the tumor 
is of utmost importance. Use of multiple cryoprobes might 
hypothetically increase the efficiency of freezing by extend-
ing the coldest isothermal line, compared with the use of 
a single probe, and the distribution of the probes across the 
tumor might also compensate for an asymmetric tumor 
shape. However, in the case of a large tumor over 4 cm, de-
spite an increase in the number of cryoprobes used, ad-
jacent deep renal structures may cause interference in re-
al-time identification and monitoring of the ice-ball. Thus, 
as shown in our results, proper consideration of the tumor 
size is the most important factor in achieving reliable onco-
logic control. In addition, the physician should keep in mind 
that increased tumor size also correlates with an increase 
in the rate of postoperative complications. This trend was 
comparable with results from Lehman et al, who reported 
a complication rate of 62% with LRC for larger renal tumors 
(over 3 cm), compared with no complications for their small-
er counterparts [10]. Similar to our results, in their series, 
blood transfusions were the most common complication. In 
conclusion, our data illustrated the intermediate-term effi-
cacy of LRC for treatment of small renal masses and a sig-
nificantly increased complication rate and tumor re-
currence rate in larger (over 4 cm) tumors.
CONCLUSIONS
Our experience with intermediate-term follow-up sug-
gests that LRC was effective for renal tumors smaller than 
3 cm without oncologic recurrence or complications. How-
ever, LRC for renal tumors larger than 3 cm was associated 
with increased transfusion rates. In addition, LRC for re-
nal tumors larger than 4 cm was associated with a sig-
nificant increase in tumor recurrence rates. In summary, 
although our data illustrate the intermediate-term effi-
cacy of LRC for treatment of small renal masses, the com-
plication rate and tumor recurrence rate were significantly 
increased in larger (over 4 cm) tumors. To ensure desirable 
oncologic efficacy, prudent patient selection for LRC will 
be imperative.
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